ciglitazone has been researched along with Coronary Artery Disease in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, HK | 1 |
| Koshy, SK | 1 |
| Wasson, S | 1 |
| Quan, EE | 1 |
| Pagni, S | 1 |
| Roberts, AM | 1 |
| Joshua, IG | 1 |
| Tyagi, SC | 1 |
1 other study available for ciglitazone and Coronary Artery Disease
| Article | Year |
|---|---|
Adaptive-outward and maladaptive-inward arterial remodeling measured by intravascular ultrasound in hyperhomocysteinemia and diabetes.
Topics: Animals; Collagen; Coronary Artery Disease; Coronary Vessels; Diabetes Complications; Diabetes Melli | 2006 |